Growth Metrics

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Diluted Average) (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 16 years, most recently at $61.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $61.0 million for Q4 2025, down 7.61% from a year ago — trailing twelve months through Dec 2025 was $61.0 million (down 7.61% YoY), and the annual figure for FY2025 was $61.0 million, down 7.61%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $61.0 million at Jazz Pharmaceuticals, down from $61.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for JAZZ hit a ceiling of $73.8 million in Q1 2023 and a floor of $58.0 million in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $62.9 million (2022), compared with a mean of $64.7 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 17.27% in 2023 and later dropped 15.23% in 2024.
  • Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $59.7 million in 2021, then grew by 4.77% to $62.5 million in 2022, then rose by 15.23% to $72.1 million in 2023, then dropped by 8.41% to $66.0 million in 2024, then decreased by 7.61% to $61.0 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $61.0 million (Q4 2025), $61.6 million (Q3 2025), and $61.1 million (Q2 2025) per Business Quant data.